← Evidence map

ArticleVaccine2023

COVID-19 mRNA BNT162b2 vaccine safety and B-cell and T-cell reactogenicity among children with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS-TS) - preliminary study.

Kamila M Ludwikowska et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.

1 paper cites it

2023

this papercites it

COVID-19 mRNA BNT162b2 vaccine safety and B-cell and T-cell reactogenicity among children with a history of paediatric multisystem inflammatory syndrome temporally associated with COVID-19 (PIMS-TS) - preliminary study. | OpenQuestion